AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03567694
Drug: HA115
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test Drug
Trial: NCT05136170
Drug: Cenegermin
RxNorm normalized name: Cenegermin
DrugBank: Cenegermin (DB13926)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
Trial: NCT06463184
Drug: Xevinapant
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
Trial: NCT04675827
Drug: Pertuzumab and tratuzumab fixed dose combination
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
Trial: NCT04675827
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment administration: adjuvant T-DM1 for 14 cycles.
Trial: NCT05559099
Drug: Tecovirimat Oral Capsule
RxNorm normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)
Trial: NCT06211712
Drug: Experimental: Human Urinary Kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
Trial: NCT06528405
Drug: dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Trial: NCT06528405
Drug: empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Trial: NCT06528405
Drug: canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Trial: NCT05990686
Drug: Tramadol Hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)
Trial: NCT05363592
Drug: Alogliptin Benzoate 12.5 mg
RxNorm normalized name: Alogliptin Benzoate 12.5 MG Oral Tablet
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
Trial: NCT05363592
Drug: Metformin HCl XR 500 mg
RxNorm normalized name: metformin hydrochloride Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
Trial: NCT04800692
Drug: Tetrahydrobiopterin 10 mg/kg
DrugBank: Biopterin (DB03886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg of Tetrahydrobiopterin daily.
Trial: NCT04800692
Drug: Tetrahydrobiopterin 20 mg/kg
DrugBank: Biopterin (DB03886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg of Tetrahydrobiopterin daily.
Trial: NCT04800692
Drug: L-Ascorbate
RxNorm normalized name: L-Ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3300 mg of l-ascorbate once daily
Trial: NCT04800692
Drug: L-Arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3400mg of l-arginine once daily
Trial: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 1
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Trial: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 2
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Trial: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 3
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Trial: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 4
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Trial: NCT00001066
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001066
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001066
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05857748
Drug: lifitegrast
RxNorm normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient newly started on medication will be followed for 6 months
Trial: NCT06650384
Drug: Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
Trial: NCT06251115
Drug: QY-1-T
RxNorm normalized name: 1-T
DrugBank: 1-Testosterone (DB01481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QY-1-T is a TCR-T drug targeting HBV-related HCC
Trial: NCT05442736
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
Trial: NCT04470024
Drug: INCAGN01876
RxNorm normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: agonistic antihuman GITR mAb
Trial: NCT05291650
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
Trial: NCT05291650
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
Trial: NCT04670796
Drug: HLX02
RxNorm normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subject receive one dose of HLX02
Trial: NCT04670796
Drug: EU-sourced Trastuzumab (Herceptin®)
RxNorm normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
Trial: NCT04670796
Drug: US-licensed Trastuzumab (Herceptin®)
RxNorm normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subject receive one dose of US-licensed Trastuzumab (Herceptin®)
Trial: NCT06173466
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
Trial: NCT06173466
Drug: Bupivacaine Hydrochloride combined with dexamethasone
RxNorm normalized name: bupivacaine hydrochloride / epinephrine Cartridge [Marcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
Trial: NCT05790447
Drug: Thymalfasin
RxNorm normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loading dose with thymalfasin based on the amounts of T lymphocyte
Trial: NCT05790447
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection daily for 7 consecutive days
Trial: NCT05863455
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ntravenous injection of an equivalent volume of saline before radial artery cannulation.
Trial: NCT05160415
Drug: Sevasemten
RxNorm normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose
Trial: NCT05348811
Drug: HAIC combined with donafenib and sintilimab
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol.
Trial: NCT05644873
Drug: magnesium sulfate group
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
Trial: NCT00000628
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05714007
Drug: Ferric derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose ferric derisomaltose
Trial: NCT05714007
Drug: Ferrous succinate
RxNorm normalized name: Ferrous succinate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
Trial: NCT05631249
Drug: Sotorasib 120Mg Tab
RxNorm normalized name: SOTORASIB 120MG TAB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
Trial: NCT05692999
Drug: Pembrolizumab 200 mg Q6W
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg Q6W
Trial: NCT05692999
Drug: Pemetrexed 500 mg/m^2 Q3W
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m\^2 Q3W
Trial: NCT05692999
Drug: Pembrolizumab 200 mg Q3W or 400 mg Q6W
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg Q3W or 400 mg Q6W
Trial: NCT04850599
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04850599
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05231980
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
Trial: NCT05231980
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: is a medication used to treat infertility in women who do not ovulate
Trial: NCT05296161
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Personalized B cell tailored ocrelizumab treatment
Trial: NCT00002414
Drug: CPI-1189
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04336826
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Trial: NCT05004415
Drug: AT-527 (R07496998)
RxNorm normalized name: AT-III
DrugBank: AT-527 (DB16451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive a single radiolabeled dose of 550 mg AT-527.
Trial: NCT06344091
Drug: Bupivacaine Liposome Injection
RxNorm normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
Trial: NCT03906357
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00399022
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05248841
Drug: HEC-Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
Trial: NCT05229614
Drug: Immunotherapy (Pembrolizumab)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
Trial: NCT05456256
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
Trial: NCT05456256
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Trial: NCT04696146
Drug: Berinert
RxNorm normalized name: Berinert
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarenal dose of 500 U of Berinert
Trial: NCT06270407
Drug: Tranexamic Acid 100 MG/ML
RxNorm normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
Trial: NCT06270407
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Trial: NCT05574179
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj precedex 200mcg in 1ml given in stat doses
Trial: NCT05574179
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj.midazolam 5mg/5ml given in stat doses
Trial: NCT06450886
Drug: Ulviprubart (ABC008)
RxNorm normalized name: Ulviprubart
DrugBank: Ulviprubart (DB18281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
Trial: NCT06226610
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: injection every two weeks while on study
Trial: NCT04976777
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 0.7 mg in a solid polymer drug delivery system
Trial: NCT05973903
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Lenvatinib 20 mg once daily
Trial: NCT05973903
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous pembrolizumab 200 mg every three weeks
Trial: NCT04551495
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
Trial: NCT04551495
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
Trial: NCT04551495
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
Trial: NCT04795531
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections